Antibody response to infliximab and its impact on pharmacokinetics can be transient

American Journal of Gastroenterology

Volumn 108, Issue 6, 2013, Pages 962-971

  Vande Casteele, Niels ^a   Gils, Ann ^a   Singh, Sharat ^b   Ohrmund, Linda ^b   Hauenstein, Scott ^b   Rutgeerts, Paul ^c   Vermeire, Séverine ^c  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b Prometheus Laboratories   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CROHN DISEASE; DRUG DOSE INCREASE; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; RETROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 84878945732     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.12     Document Type: Article

References (29)

1. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infl iximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 ; 353 : 2462-76. (Pubitemid 41770166)
2. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infl iximab for Crohn's disease: the ACCENT I randomised trial. Lancet England 2002 ; 359 : 1541-9. (Pubitemid 34621118)
3. Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infl iximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011 ; 141 : 1194-201.
4. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in infl ammatory bowel diseases: defi nitions, frequency and pharmacological aspects. J Crohns Colitis 2010 ; 4 : 355-66.
5. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011 ; 305 : 1460-8.
6. Karmiris K, Paintaud G, Noman M et al. Infl uence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009 ; 137 : 1628-40.
7. Baert F, Noman M, Vermeire S et al. Infl uence of immunogenicity on the longterm effi cacy of infl iximab in Crohn's disease. N Engl J Med 2003 ; 348 : 601-8.
8. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infl iximab aft er maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 ; 2 : 542-53. (Pubitemid 38834038)
9. Sands BE, Anderson FH, Bernstein CN et al. Infl iximab maintenance therapy for fi stulizing Crohn's disease. N Engl J Med 2004 ; 350 : 876-85. (Pubitemid 38252535)
10. Vande Casteele N, Breynaert C, Vermeire S et al. Incidence of acute severe infusion reactions to infl iximab depends on defi nition used rather than assay. Aliment Pharmacol Th er 2011 ; 34 : 401-3.
11. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infl iximab to clinical outcome aft er scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006 ; 4 : 1248-54. (Pubitemid 44512213)
12. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infl iximab on clinical outcomes and serum infl iximab levels in patients with infl ammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2012 ; 108 : 40-7.
13. Ben-Horin S, Yavzori M, Katz L et al. Th e immunogenic part of infl iximab is the F(ab ' )2, but measuring antibodies to the intact infl iximab molecule is more clinically useful. Gut England 2011 ; 60 : 41-8.
14. Ordas I, Mould DR, Feagan BG et al. Anti-TNF monoclonal antibodies in infl ammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Th er 2012 ; 91 : 635-46.
15. Vermeire S, Noman M, Van Assche G et al. Eff ectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infl iximab in Crohn's disease. Gut 2007 ; 56 : 1226-31. (Pubitemid 47300423)
16. Seow CH, Newman A, Irwin SP et al. Trough serum infl iximab: a predictive factor of clinical outcome for infl iximab treatment in acute ulcerative colitis. Gut England 2010 ; 59 : 49-54.
17. Vande Casteele N, Ballet V, Van Assche G et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infl iximab and adalimumab treatment. Gut 2012 ; 61 : 321.
18. Wang SL, Ohrmund L, Hauenstein S et al. Development and validation of a homogeneous mobility shift assay for the measurement of infl iximab and antibodies-to-infl iximab levels in patient serum. J Immunol Methods 2012 ; 382 : 177-88.
19. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Anti-infl iximab and anti-adalimumab antibodies in relation to response to adalimumab in infl iximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis England 2010 ; 69 : 817-21.
20. Wolbink GJ, Vis M, Lems W et al. Development of antiinfl iximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006 ; 54 : 711-5.
21. Ducourau E, Mulleman D, Paintaud G et al. Antibodies toward infl iximab are associated with low infl iximab concentration at treatment initiation and poor infl iximab maintenance in rheumatic diseases. Arthritis Res Th er 2011 ; 13 : R105.
22. Gottlieb AB, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infl iximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003 ; 48 : 68-75. (Pubitemid 36091536)
23. Steenholdt C, Al-Khalaf M, Brynskov J et al. Clinical implications of variations in anti-infl iximab antibody levels in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2012 ; 18 : 2209-17.
24. Afi f W, Loft us EV Jr, Faubion WA et al. Clinical utility of measuring infl iximab and human anti-chimeric antibody concentrations in patients with infl ammatory bowel disease. Am J Gastroenterol 2010 ; 105 : 1133-9.
25. Cornillie F, Hanauer S, Diamond R et al. Early serum infl iximab trough level, clinical disease activity and CRP as markers of sustained benefi t of infl iximab treatment in Crohn's disease: a post-hoc analysis of the ACCENT1 trial. Am J Gastroenterol 2011 ; 106 : S462-3.
26. Katz L, Gisbert JP, Manoogian B et al. Doubling the infl iximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Infl amm Bowel Dis 2012 ; 18 : 2026-33.
27. Pariente B, Pineton de Chambrun G, Krzysiek R et al. Trough levels and antibodies to infl iximab may not predict response to intensifi cation of infl iximab therapy in patients with infl ammatory bowel disease. Infl amm Bowel Dis 2012 ; 18 : 1199-206.
28. Vande Casteele N, Buurman DJ, Sturkenboom MG et al. Detection of infl iximab levels and anti-infl iximab antibodies: a comparison of three diff erent assays. Aliment Pharmacol Th er 2012 ; 36 : 765-71.
29. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide " Tregitopes ". Blood 2008 ; 112 : 3303-11.